SSA
PALI icon

Schonfeld Strategic Advisors’s Palisade Bio PALI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,146
Closed -$58K – 2903
2026
Q1 		$58K Buy
33,146
+21,915
+195% +$39.9K ﹤0.01% 1949
2025
Q4 		$26.4K Buy
+11,231
New +$21.6K ﹤0.01% 1914

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Schonfeld Strategic Advisors's PALI Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Palisade Bio (PALI) in Q2 2026, closing a stake of 33,146 shares — an estimated $58K sold.

Schonfeld Strategic Advisors first reported a position in PALI in Q4 2025 and held it in 2 quarters. The position peaked at $58K in Q1 2026. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Palisade Bio position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 33,146 Palisade Bio shares in Q2 2026, an estimated $58K.
  • Schonfeld Strategic Advisors first reported a position in Palisade Bio in Q4 2025 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Palisade Bio position peaked at $58K in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.